[3-(1,4'-联哌啶-1'-基)丙基]胺 | 890141-58-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: [3-(1,4'-联哌啶-1'-基)丙基]胺
• 英文名称: 3-([1,4'-bipiperidin]-1'-yl)propan-1-amine
• 英文别名: [3-(1,4'-Bipiperidin-1'-yl)propyl]amine；3-(4-piperidin-1-ylpiperidin-1-yl)propan-1-amine
• CAS: 890141-58-9
• 化学式: C₁₃H₂₇N₃
• mdl: MFCD14282106
• 分子量: 225.377
• InChiKey: JULHFSWCDLKJNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  [3-(1,4'-联哌啶-1'-基)丙基]胺 在 盐酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 11.0h， 生成 2-(3-[1,4']Bipiperidinyl-1'-yl-propyl)-3-oxo-2,3-dihydro-1H-isoindole-4-carboxylic acid
  参考文献：
  名称：

  Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy

  摘要：

  The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) has a well-established role in the signaling and repair of DNA and is a prominent target in oncology, as testified by the number of candidates in clinical testing that unselectively target both PARP-1 and its closest isoform PARP-2. The goal of our program was to find a PARP-1 selective inhibitor that would potentially mitigate toxicities arising from cross-inhibition of PARP-2. Thus, an HTS campaign on the proprietary Nerviano Medical Sciences (NMS) chemical collection, followed by SAR optimization, allowed us to discover 2-[1-4,4-difluorocyclohexyl)piperidin-4-yl] -6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118, 20by). NMS-P118 proved to be a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles and high efficacy in vivo both as a single agent and in combination with Temozolomide in MDA-MB-436 and Capan-1 xenograft models, respectively. Cocrystal structures of 20by with both PARP-1 and PARP-2 catalytic domain proteins allowed rationalization of the observed selectivity.

  DOI：

  10.1021/acs.jmedchem.5b00680
• 作为产物：
  描述：

  4-哌啶基哌啶 在 potassium carbonate 、 一水合肼 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 13.0h， 生成 [3-(1,4'-联哌啶-1'-基)丙基]胺
  参考文献：
  名称：

  [EN] COMPOUNDS FOR TREATING VIRAL INFECTIONS
  [FR] COMPOSÉS POUR TRAITER DES INFECTIONS VIRALES

  摘要：

  本发明涉及小分子化合物及其在治疗疾病中的应用，特别是病毒性疾病，尤其是丙型肝炎病毒（HCV）。

  公开号：

  WO2015158908A1

文献信息

• COMPOUNDS FOR TREATING DIABETES
  申请人：Ohr Pharmaceutical, Inc.

  公开号：EP2188299B1

  公开（公告）日：2017-10-25
• COMPOUNDS FOR TREATING VIRAL INFECTIONS
  申请人：Institut Pasteur Korea

  公开号：EP3131890A1

  公开（公告）日：2017-02-22
• US9809602B2
  申请人：——

  公开号：US9809602B2

  公开（公告）日：2017-11-07
• [EN] BENZODIAZEPINE BRADYKININ ANTAGONISTS<br/>[FR] BENZODIAZEPINES ANTAGONISTES DE BRADYKININE
  申请人：MERCK & CO INC

  公开号：WO2002099388A2

  公开（公告）日：2002-12-12

  Compounds disclosed here or a pharmaceutically acceptable salt thereof, are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
• [EN] AZAHETEROCYCLES, COMBINATORY LIBRARY, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE PRODUCTION THEREOF<br/>[FR] BIBLIOTHÈQUES COMBINATOIRE ET FOCALISÉE D'AZAHÉTÉROCYCLES, COMPOSITION PHARMACEUTIQUE ET PROCÉDÉS DE LEUR FABRICATION
  申请人：CHEMICAL DIVERSITY RES INST LT

  公开号：WO2007117180A1

  公开（公告）日：2007-10-18

  [EN] The invention relates to novel azaheterocycles of interest as potential physiologically active substances (agonists, antagonists, receptor modulators, ferment inhibitors, oncolytics, antibacterial and antiparasitic agent etc.), to combinatory and focused libraries comprising novel azaheterocycles of a pharmaceutical composition containing said novel azaheterocycles in the form of an active substance and to methods for the production and the use thereof. Said novel azaheterocycles are of general formula (1), wherein W is an azaheterocycle which comprises 6-12 atoms, is optionally annelated, has at least one C₅-C₇ carbocycle and/or heterocycle, and also comprises at least one of heteroatoms and is selected from an O, S or N group; R₁
  [FR] L'invention concerne de nouveaux azahétérocycles qui représentent un intérêt certain en tant que substances physiologiquement actives potentielles (agonistes, antagonistes et modulateurs de récepteurs, inhibiteurs de ferments, oncolytiques, antibactériens, antiparasitaires, etc.), des bibliothèques combinatoire et focalisée comprenant de nouveaux azahétérocycles, une composition pharmaceutique contenant en tant que substance active de nouveaux azahétérocycles, leurs procédés de fabrication et d'utilisation. L'invention porte sur de nouveaux azahétérocycles ayant la formule générale (1), dans laquelle W est un hétérocycle comprenant de 6 à 12 atomes éventuellement hybridé à un carbocycle et/ou hétérocycle C₅-C₇, qui comprend au moins un hétéro-atome sélectionné dans le groupe O, S ou N, R₁